|
|
|
|
The evidence for the effectiveness of nimodipine is not beyond doubt, but given the potential benefits and modest risks of this treatment, against the background of a devastating natural history, oral nimodipine (60 mg every 4 h) is currently indicated in patients with aneurismal SAH. Intravenous administration of calcium antagonists cannot be recommended for routine practice on the basis of the present evidence. |
|